Roche, Tadzio R.
Wetli, Doreen J.
Braun, Julia
Kataife, Ezequiel D.
Mileo, Federico G.
Spahn, Donat R.
Tscholl, David W.
Said, Sadiq
Article History
Received: 25 November 2020
Accepted: 4 February 2021
First Online: 10 February 2021
Ethics approval and consent to participate
: The Cantonal Ethics Committee of Zurich in Switzerland reviewed the study protocol and issued a declaration of no objection (Business Management System for Ethics Committees Number 2019–01090). The ethics committee responsible for the center in Buenos Aires approved the study protocol in a separate statement (N° 5357, dated November 14th, 2019). Before participation, we obtained written informed consent from all participants to the anonymous use of their data.
: Not applicable.
: D.R.S.’s academic department is receiving grant support from the Swiss National Science Foundation, Berne, Switzerland, the Swiss Society of Anesthesiology and Reanimation (SGAR), Berne, Switzerland, the Swiss Foundation for Anesthesia Research, Zurich, Switzerland, Vifor SA, Villars-sur-Glâne, Switzerland, and Vifor (International) AG, St. Gallen, Switzerland.D.R.S. is co-chair of the ABC-Trauma Faculty, sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland, CSL Behring GmbH, Marburg, Germany, LFB Biomédicaments, Courtaboeuf Cedex, France and Octapharma AG, Lachen, Switzerland.D.R.S. received honoraria/travel support for consulting or lecturing from: Danube University of Krems, Austria, US Department of Defense, Washington, USA, European Society of Anesthesiology, Brussels, BE, Korean Society for Patient Blood Management, Seoul, Korea, Korean Society of Anesthesiologists, Seoul, Korea, Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Paris, France, Baxalta Switzerland AG, Volketswil, Switzerland, Bayer AG, Zürich, Switzerland, B. Braun Melsungen AG, Melsungen, Germany, Boehringer Ingelheim GmbH, Basel, Switzerland, Bristol-Myers-Squibb, Rueil-Malmaison Cedex, France and Baar, Switzerland, CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland, Celgene International II Sàrl, Couvet, Switzerland, Daiichi Sankyo AG, Thalwil, Switzerland, Haemonetics, Braintree, MA, USA, Instrumentation Laboratory (Werfen), Bedford, MA, USA, LFB Biomédicaments, Courtaboeuf Cedex, France, Merck Sharp & Dohme, Kenilworth, New Jersey, USA, PAION Deutschland GmbH, Aachen, Germany, Pharmacosmos A/S, Holbaek, Denmark, Pfizer AG, Zürich, Switzerland, Pierre Fabre Pharma, Alschwil, Switzerland, Portola Schweiz GmbH, Aarau, Switzerland, Roche Diagnostics International Ltd., Reinach, Switzerland, Sarstedt AG & Co., Sevelen, Switzerland and Nümbrecht, Germany, Shire Switzerland GmbH, Zug, Switzerland, Tem International GmbH, Munich, Germany, Vifor Pharma, Munich, Germany, Neuilly sur Seine, France and Villars-sur-Glâne, Switzerland, Vifor (International) AG, St. Gallen, Switzerland, Zuellig Pharma Holdings, Singapore, Singapore.D.W.T. designated inventor of the technology Visual Clot, which is owned by the University of Zurich. D.W.T. may receive royalties in the event of commercialization of this technology. D.W.T. designated inventor of the technology Visual Patient, which is owned by the University of Zurich. This technology has been licensed to Koninklijke Philips N.V., Amsterdam, The Netherlands. D.W.T. may receive royalties based on the commercial success of the technology. D.W.T. received travel support for consulting Instrumentation Laboratory, Bedford, MA, U.S.A.The other authors do not have any competing interests.